Navigation Links
GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
Date:8/27/2010

icipants.  She also indicated the screening of the Therapeutic Trial volunteers is on target to begin generating vaccine safety and performance data during 2011, with trial completion within 24 to 36 months.  Mark Reynolds, chief financial officer, provided a financial update and discussed the Company's sources of capital.

HIV/AIDS BackgroundHIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America where there are roughly 60,000 new infections each year. Globally, there are about 2.5 million AIDS infections per year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3 million people living with AIDS in North America and 33.2 million people living with AIDS worldwide. Presently, there is little to prevent HIV transmission other than education, circumcision, and condoms. It is obvious from the spread of the disease that these methods are not adequate. Existing treatments for individuals infected with HIV include anti-retroviral therapies that are effective but have serious medical side effects and are very expensive (upwards of $1,500/month). This cost is borne primarily by the individual and sometimes by third party insurance, local healthcare, federal or world health organizations. Development and distribution of an effective HIV/AIDS vaccine holds great promise. The GeoVax vaccine would cost a fraction of the cost of current treatments and, to date, has not elicited serious adverse side effects in several human trials. A population vaccinated with an effective HIV-1 vaccine would be expected to significantly decrease the prevalence of AIDS over time.

About GeoVax Labs, Inc.GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, oversee manufacturing and testing of
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
6. GeoVax to Present at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax to Exhibit at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 HubCast® Inc. ( http://www.hubcast.com ), ... the expansion of its Global Print Supply Chain with ... the world’s largest cities across 75 countries globally. ... countries providing global enterprises ease, speed, reach, quality, cost ... online order to real-world delivery at postal address around ...
(Date:3/3/2015)... March 3, 2015 Kindred Biosciences, Inc. (NASDAQ: ... improving the lives of pets, announced today that it will ... March 12, 2015 after the market close. The Company will ... day. Interested parties may access the call ... 756-4262 internationally, and using conference ID 98449349.  ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research and ... addition of Jain PharmaBiotech,s new report "RNAi - ... , Because of its ability to silence ... been adopted as the research tool to discriminate gene ... RNAi can be designed to target every gene in ...
(Date:3/3/2015)... , March 3, 2015  Synthetic Biologics, Inc. (NYSE ... and diseases, with a focus on protecting the microbiome, announced ... scheduled to present at the 27th Annual ROTH Conference being ... Laguna Niguel in Dana Point, CA. ... March 10, 2015 at 1:00 p.m. (Pacific Time). ...
Breaking Biology Technology:HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... Global Biotechnology Company Adopts Pharsight,s Groundbreaking ... Automation Software, ... ), a leading provider of software and strategic,services for optimizing clinical ... purchased WinNonlin AutoPilot.,This sale marks Pharsight,s third new customer win since ...
... Denosumab is a new drug being,studied to prevent fractures ... phase 3 clinical trial using denosumab were presented,Friday evening ... MD, from the Seattle Cancer Care Alliance., Denosumab ... osteoclasts -- specialized cells that break down bone. Because ...
... Dec. 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX:,MS), ... sclerosis (MS), today,announced that following the meeting of ... has received a recommendation to,continue MAESTRO-01, its pivotal ... of secondary progressive multiple sclerosis., This was ...
Cached Biology Technology:Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer 2Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer 3New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment 2BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... or Genetically Modified Organisms, may raise concerns of genes escaping ... But what is the real risk that traits associated ... wild relatives? Interest in plant ecology, crop production and ... University of Nebraska and USDA-ARS to investigate how gene flow ...
... Newport News, Virginia, was walking her employer,s Westie around the ... mysterious blob floating in the water. Co-worker Charlie Schmuck ... by the lake, saw the object, and asked everyone else ... it was "a huge dead snake." Charlie thought it ...
... The rate at which lead poisoning has struck young Rhode ... a Brown University-led geographic analysis of comprehensive health department data ... cases of lead poisoning, researchers have been able to help ... that 12-year period, some census blocks in the state had ...
Cached Biology News:If GMO genes escape, how will the hybrids do? 2If GMO genes escape, how will the hybrids do? 3VIMS scientists help solve mystery of 'alien pod' 2Lead poisoning maps in R.I. reveal huge disparities, guide cleanup 2